Serum Periostin as a Unique Biomarker of Bronchial Asthma
/ 0
- Details
- Category: Vol. 85, December 2017
- Hits: 514
Serum Periostin as a Unique Biomarker of Bronchial Asthma, MARIAM M. AMIN, MONA A. KHATTAB, SOMIA A. HASSAN and HODA A. ABDEL SATTAR
Abstract
Background: Bronchial asthma is characterized by type 2 cytokine eosinophilic airway inflammation. In spite of this fact, it is heterogeneous. It is important to stratify bronchial asthma for optimized therapy to increase the efficacy of treatment and reduce costs. Periostin has emerged as a biomar-ker for bronchial asthma.
Aim of the Study: Measure serum Periostin and IL-13 in asthmatic patients and decide whether their levels vary with the level of asthma control, sputum and peripheral eosinophilic count, associated atopic manifestations and steroid respon-siveness.
Methodology: Serum levels of IL13 and periostin were measured in sixty adult asthmatic patients. Thirty healthy individuals (group matched) served as control group. Data was collected regarding clinical history and specific investi-gations (skin prick test, pulmonary function test, serum total immunoglobulin E, peripheral absolute eosinophilic count and sputum analysis for eosinophil).
Results: Regarding sputum and blood eosinophilia, serum total IgE, IL13 and periostin, a statistically significant increase were found in asthmatic patients compared to healthy controls (p<0.01). Serum periostin was elevated more in cases of uncontrolled asthma, severe airway obstruction, increased blood and sputum eosinophils, steroid resistance, and associ-ated atopic diseases with statistical significance. Highly significant negative correlation was found between serum periostin and age (r=–0.608), age of asthma onset (r=–0.466), duration of the disease (r=–0.474) and being positive in correlation to serum total IgE (r=0.63, p<0.01). However, no significant correlation was found between serum periostin and IL13.
Conclusion: Serum periostin can be useful for both diag-nosis and categorizing asthma patients.